Travere Therapeutics (NASDAQ: TVTX) presented extended results from its Phase 3 DUPLEX study of FILSPARI at the European Renal Association ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE